NL301357I2 - combinatie van (a) vanzacaftor of een farmaceutisch aanvaardbaar zout daarvan, bij voorkeur een calciumzout daarvan, (b) tezacaftor of een farmaceutisch aanvaardbaar zout daarvan, en (c) deutivacaftor of een farmaceutisch aanvaardbaar zout daarvan - Google Patents
combinatie van (a) vanzacaftor of een farmaceutisch aanvaardbaar zout daarvan, bij voorkeur een calciumzout daarvan, (b) tezacaftor of een farmaceutisch aanvaardbaar zout daarvan, en (c) deutivacaftor of een farmaceutisch aanvaardbaar zout daarvanInfo
- Publication number
- NL301357I2 NL301357I2 NL301357C NL301357C NL301357I2 NL 301357 I2 NL301357 I2 NL 301357I2 NL 301357 C NL301357 C NL 301357C NL 301357 C NL301357 C NL 301357C NL 301357 I2 NL301357 I2 NL 301357I2
- Authority
- NL
- Netherlands
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- salt
- vanzacaftor
- deutivacaftor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862767202P | 2018-11-14 | 2018-11-14 | |
| PCT/US2019/061171 WO2020102346A1 (en) | 2018-11-14 | 2019-11-13 | Methods of treatment for cystic fibrosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL301357I2 true NL301357I2 (nl) | 2026-02-05 |
Family
ID=68808572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL301357C NL301357I2 (nl) | 2018-11-14 | 2025-12-15 | combinatie van (a) vanzacaftor of een farmaceutisch aanvaardbaar zout daarvan, bij voorkeur een calciumzout daarvan, (b) tezacaftor of een farmaceutisch aanvaardbaar zout daarvan, en (c) deutivacaftor of een farmaceutisch aanvaardbaar zout daarvan |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20220047564A1 (nl) |
| EP (2) | EP3880197B9 (nl) |
| AU (1) | AU2019381750B2 (nl) |
| BR (1) | BR112021009145A2 (nl) |
| CA (1) | CA3123578A1 (nl) |
| CL (1) | CL2021001248A1 (nl) |
| CO (1) | CO2021007447A2 (nl) |
| DK (1) | DK3880197T3 (nl) |
| EA (1) | EA202191361A1 (nl) |
| ES (1) | ES2943126T3 (nl) |
| FI (2) | FI3880197T3 (nl) |
| FR (1) | FR25C1049I1 (nl) |
| HR (1) | HRP20230272T1 (nl) |
| HU (2) | HUE061686T2 (nl) |
| IL (1) | IL282988B2 (nl) |
| LT (2) | LT3880197T (nl) |
| MA (1) | MA54227B1 (nl) |
| MD (1) | MD3880197T3 (nl) |
| NL (1) | NL301357I2 (nl) |
| NO (1) | NO2025052I1 (nl) |
| PL (1) | PL3880197T3 (nl) |
| PT (1) | PT3880197T (nl) |
| RS (1) | RS64192B9 (nl) |
| SI (1) | SI3880197T1 (nl) |
| SM (1) | SMT202300102T1 (nl) |
| WO (1) | WO2020102346A1 (nl) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117924170A (zh) * | 2017-12-01 | 2024-04-26 | 弗特克斯药品有限公司 | 用于制备囊性纤维化跨膜传导调节因子的调节剂的方法 |
| CA3088577A1 (en) | 2018-02-15 | 2019-08-22 | Vertex Pharmaceuticals Incorporated | Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cycstic fibrosis, and process for making them |
| TWI848092B (zh) | 2019-04-03 | 2024-07-11 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白調節劑 |
| IL290408B2 (en) * | 2019-08-14 | 2025-10-01 | Vertex Pharma | Cystic fibrosis transmembrane conductance regulator modulators |
| US11873300B2 (en) * | 2019-08-14 | 2024-01-16 | Vertex Pharmaceuticals Incorporated | Crystalline forms of CFTR modulators |
| TWI867024B (zh) | 2019-08-14 | 2024-12-21 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
| TWI899097B (zh) | 2019-08-14 | 2025-10-01 | 美商維泰克斯製藥公司 | 製備cftr調節劑之方法 |
| CR20230120A (es) | 2020-08-07 | 2023-09-01 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
| WO2022036060A1 (en) | 2020-08-13 | 2022-02-17 | Vertex Pharmaceuticals Incorporated | Crystalline forms of cftr modulators |
| US12612416B2 (en) | 2020-10-07 | 2026-04-28 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| US12324802B2 (en) | 2020-11-18 | 2025-06-10 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| IL303519A (en) * | 2020-12-10 | 2023-08-01 | Vertex Pharma | Cystic fibrosis treatment methods |
| CN116829148A (zh) * | 2020-12-10 | 2023-09-29 | 弗特克斯药品有限公司 | 治疗囊性纤维化的方法 |
| IL314691A (en) | 2022-02-03 | 2024-10-01 | Vertex Pharma | PREPARATION METHODS AND CRYSTALLINE FORMS OF (6A,12A)-17-AMINO-12-METHYL-6,15-BIS(TRIFLUOROMETHYL)-13,19-DIOXA-3,4,18-TRIAZATRICYCLO[ 12.3.112.3.1. NONADECA-1(18),2,4,14,16-PENTAEN-6-OL |
| CA3249378A1 (en) | 2022-02-03 | 2023-08-10 | Vertex Pharmaceuticals Incorporated | TREATMENT METHODS FOR CYSTIC FIBROSIS |
| CN118974059A (zh) | 2022-02-08 | 2024-11-15 | 弗特克斯药品有限公司 | 囊性纤维化跨膜传导调控因子的调节剂 |
| WO2023224924A1 (en) | 2022-05-16 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | Solid forms of a macrocyclic compounds as cftr modulators and their preparation |
| CA3253026A1 (en) | 2022-05-16 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | TREATMENT METHODS FOR CYSTIC FIBROSIS |
| WO2025166342A1 (en) | 2024-02-04 | 2025-08-07 | Vertex Pharmaceuticals Incorporated | Combination of vanzacaftor, tezacaftor, deutivacaftor for use in treating cystic fibrosis |
| DK4648753T3 (da) | 2024-02-07 | 2026-02-23 | Vertex Pharma | Sammensætninger til behandling af cftr-medierede sygdomme |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2672549A1 (en) | 2001-11-14 | 2003-06-12 | Ben-Zion Dolitzky | Amorphous and crystalline forms of losartan potassium and process for their preparation |
| AU2007249269A1 (en) | 2006-05-12 | 2007-11-22 | Vertex Pharmaceuticals Incorporated | Compositions of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl)-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| KR20110042356A (ko) | 2008-08-13 | 2011-04-26 | 버텍스 파마슈티칼스 인코포레이티드 | 제약 조성물 및 그의 투여 |
| AU2009296271A1 (en) | 2008-09-29 | 2010-04-01 | Vertex Pharmaceuticals Incorporated | Dosage units of 3-(6-(1-(2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
| LT2826776T (lt) | 2010-03-25 | 2021-01-11 | Vertex Pharmaceuticals Incorporated | (r)-1(2,2-difluorbenzo(d)(1,3)dioksol-5-il)-n-(1-(2,3-dihidroksipropil)-6-fluor-2-(1-hidroksi-2-metilpropan-2-il)-1h-indol-5-il)-ciklopropankarboksamido kieta amorfinės formos dispersija |
| RS62767B1 (sr) | 2010-04-07 | 2022-01-31 | Vertex Pharma | Farmaceutski sastavi 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiriodin-2-il)benzojeve kiseline i njihova primena |
| CN105130948A (zh) | 2010-04-22 | 2015-12-09 | 弗特克斯药品有限公司 | 制备环烷基甲酰胺基-吲哚化合物的方法 |
| AU2011242452A1 (en) | 2010-04-22 | 2012-11-08 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
| NZ607494A (en) | 2010-08-27 | 2015-04-24 | Vertex Pharma | Pharmaceutical composition and administrations thereof |
| HUE047354T2 (hu) | 2011-05-18 | 2020-04-28 | Vertex Pharmaceuticals Europe Ltd | Ivacaftor deuterizált származékai |
| JP2015511583A (ja) | 2012-02-27 | 2015-04-20 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | 薬学的組成物およびその投与 |
| CA2878057A1 (en) | 2012-07-16 | 2014-01-23 | Rossitza Gueorguieva Alargova | Pharmaceutical compositions of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof |
| SMT202500078T1 (it) | 2012-11-02 | 2025-03-12 | Vertex Pharma | Composizioni farmaceutiche per il trattamento di malattie mediate da cftr |
| JP6543268B2 (ja) | 2014-04-15 | 2019-07-10 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | 嚢胞性線維症膜コンダクタンス調節因子が媒介する疾患を処置するための医薬組成物 |
| RS60906B1 (sr) * | 2014-10-06 | 2020-11-30 | Vertex Pharma | Modulatori regulatora transmembranske provodljivosti za cističnu fibrozu |
| US20180353500A1 (en) | 2015-09-21 | 2018-12-13 | Vertex Pharmaceuticals (Europe) Limited | Administration of deuterated cftr potentiators |
| LT3519401T (lt) | 2016-09-30 | 2021-11-25 | Vertex Pharmaceuticals Incorporated | Cistinės fibrozės transmembraninio laidumo reguliavimo moduliatorius, farmacinės kompozicijos, gydymo būdai ir moduliatoriaus gamybos būdas |
| AU2017352206B2 (en) | 2016-10-27 | 2022-03-03 | Vertex Pharmaceuticals (Europe) Limited | Methods of treatment with deuterated CFTR potentiators |
| WO2019018395A1 (en) * | 2017-07-17 | 2019-01-24 | Vertex Pharmaceuticals Incorporated | METHODS OF TREATING CYSTIC FIBROSIS |
| CA3069225A1 (en) * | 2017-07-17 | 2019-01-24 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| TWI810243B (zh) * | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| CA3088577A1 (en) | 2018-02-15 | 2019-08-22 | Vertex Pharmaceuticals Incorporated | Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cycstic fibrosis, and process for making them |
-
2019
- 2019-11-13 SM SM20230102T patent/SMT202300102T1/it unknown
- 2019-11-13 PL PL19817037.5T patent/PL3880197T3/pl unknown
- 2019-11-13 HR HRP20230272TT patent/HRP20230272T1/hr unknown
- 2019-11-13 SI SI201930490T patent/SI3880197T1/sl unknown
- 2019-11-13 BR BR112021009145-9A patent/BR112021009145A2/pt unknown
- 2019-11-13 EP EP19817037.5A patent/EP3880197B9/en active Active
- 2019-11-13 ES ES19817037T patent/ES2943126T3/es active Active
- 2019-11-13 CA CA3123578A patent/CA3123578A1/en active Pending
- 2019-11-13 PT PT198170375T patent/PT3880197T/pt unknown
- 2019-11-13 WO PCT/US2019/061171 patent/WO2020102346A1/en not_active Ceased
- 2019-11-13 LT LTEPPCT/US2019/061171T patent/LT3880197T/lt unknown
- 2019-11-13 US US17/293,632 patent/US20220047564A1/en active Pending
- 2019-11-13 FI FIEP19817037.5T patent/FI3880197T3/fi active
- 2019-11-13 MD MDE20210905T patent/MD3880197T3/ro unknown
- 2019-11-13 RS RS20230317A patent/RS64192B9/sr unknown
- 2019-11-13 IL IL282988A patent/IL282988B2/en unknown
- 2019-11-13 EP EP23154663.1A patent/EP4218754B1/en active Active
- 2019-11-13 MA MA54227A patent/MA54227B1/fr unknown
- 2019-11-13 EA EA202191361A patent/EA202191361A1/ru unknown
- 2019-11-13 AU AU2019381750A patent/AU2019381750B2/en active Active
- 2019-11-13 HU HUE19817037A patent/HUE061686T2/hu unknown
- 2019-11-13 DK DK19817037.5T patent/DK3880197T3/da active
-
2021
- 2021-05-12 CL CL2021001248A patent/CL2021001248A1/es unknown
- 2021-06-08 CO CONC2021/0007447A patent/CO2021007447A2/es unknown
-
2025
- 2025-12-01 FR FR25C1049C patent/FR25C1049I1/fr active Active
- 2025-12-02 HU HUS2500048C patent/HUS2500048I1/hu unknown
- 2025-12-04 FI FIC20253012C patent/FIC20253012I1/fi unknown
- 2025-12-04 NO NO2025052C patent/NO2025052I1/no unknown
- 2025-12-10 LT LTPA2025543C patent/LTPA2025543I1/lt unknown
- 2025-12-15 NL NL301357C patent/NL301357I2/nl unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL301356I2 (nl) | vanzacaftor of een farmaceutisch aanvaardbaar zout daarvan, bij voorkeur een calciumzout daarvan | |
| NO2025052I1 (no) | a combination of (a) vanzacaftor or a pharmaceutically acceptable salt thereof, preferably a calcium salt thereof, (b) tezacaftor or a pharmaceutically acceptable salt thereof, and (c) deutivacaftor or a pharmaceutically acceptable salt thereof | |
| NL301279I2 (nl) | Adagrasib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout | |
| NL301344I2 (nl) | lnavolisib of een farmaceutisch aanvaardbaar zout daarvan | |
| NL301286I2 (nl) | Danicopan, of een farmaceutisch aanvaardbaar zout ervan | |
| FIC20260007I1 (fi) | Vimseltinibi, valinnaisesti farmaseuttisesti hyväksyttävän suolan muodossa | |
| NL301342I2 (nl) | Elafibranor, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout | |
| NL301128I2 (nl) | Risdiplam of een farmaceutisch aanvaardbaar zout daarvan | |
| NL301111I2 (nl) | Entrectinib of een farmaceutisch aanvaardbaar zout daarvan | |
| EP3630067A4 (en) | GIVING A BIPHASIC CANNABINOID | |
| NO2024009I1 (no) | Gefapixant, or a pharmaceutically acceptable salt thereof | |
| HUE062277T2 (hu) | RIP1 inhibitorvegyületek, valamint ezek elõállítása és alkalmazása | |
| MX387115B (es) | Métodos para tratar la influenza. | |
| NO2026006I1 (no) | Elinzanetant or a pharmaceutically acceptable salt thereof | |
| HUE054103T2 (hu) | Izokinolin-3-il-karboxamidok, ezek elõállítása és alkalmazása | |
| LT3658140T (lt) | Aprocitentano ir kitų veikliųjų sudedamųjų dalių deriniai, skirti atsparios hipertenzijos gydymui | |
| CY1121464T1 (el) | Στεροειδης ενωση για χρηση στην αντιμετωπιση της ηπατικης εγκεφαλοπαθειας | |
| HUE071358T2 (hu) | Benzolszulfonamid vegyületek és terápiás szerként való alkalmazásuk | |
| IL272446A (en) | Penta-condensed hexa-heterocyclic compounds, method for their preparation, drug combination and use thereof | |
| LT3268374T (lt) | Kv1.3 inhibitoriai ir jų medicininis pritaikymas | |
| NL301306I2 (nl) | Delgocitinib of een farmaceutisch aanvaardbaar zout daarvan | |
| HUE060980T2 (hu) | Kompozíciók és eljárások sebkezeléshez | |
| HUE055468T2 (hu) | Új vegyület és gyógyszerészetileg elfogadható sója | |
| EP3642619A4 (en) | NANOPORE SEQUENCERS | |
| EP3630113A4 (en) | PHARMACEUTICAL COMPOSITION INCLUDING A PDE9 INHIBITOR |